A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel-group, Single-centre Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD3199 (a B2-agonist) Given Once Daily as Inhaled Formulation Via Turbuhaler to Healthy Men
Phase of Trial: Phase I
Latest Information Update: 11 Jun 2014
At a glance
- Drugs AZD 3199 (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors AstraZeneca
- 01 May 2009 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.
- 01 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Nov 2008 Status changed from recruiting to active, no longer recruiting.